Hospira is voluntarily recalling three lots of the injectable opioid medication Hydromorphone HCl because the glass vials may be broken or cracked, the Food and Drug Administration announced yesterday. Hospira has notified hospitals and others with an existing inventory of the lots subject to this recall that they should stop use and distribution of the remaining units and quarantine them immediately. See the FDA announcement for more information, including the lot numbers. Health care professionals are encouraged to report any related problems or events to the FDA's MedWatch Program. Last week, the AHA and others asked the Drug Enforcement Administration to temporarily adjust the aggregate production quotas for certain injectable opioid medications in short supply to allow other manufacturers to supply product until the shortages resolve.
 

Related News Articles

Headline
The Centers for Disease Control and Prevention has partnered with Medscape to offer free online training on its recommendations for vaccinating homeless people…
Headline
The HPV vaccine could prevent an estimated 92% of cancers caused by the human papillomavirus in the United States, according to a new study by the Centers for…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response will provide $23 million for Merck to produce…
Headline
The Food and Drug Administration yesterday approved a new antibiotic to treat adults with community-acquired bacterial pneumonia.
Headline
The number of U.S. hospitals with an antibiotic stewardship program that meets all core elements recommended by the Centers for Disease Control and Prevention…
Headline
The Centers for Medicare…